Veerle Pertz

Learn More
Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the(More)
Department of Biology, Pisa University, Pisa, Italy; Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy; Department of Internal Medicine and Biomedical Science, Hematology and BMT Center, Parma University, Parma, Italy; Haematology Service – S Annunziata Hospital, Cosenza, Italy; Department of(More)
  • 1